A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Inclusion Criteria: * Have type 2 diabetes * Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening * Have a BMI of ≥27 kg/m2 at screening * Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have taken any of the following within 90 days prior to screening * medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies * dipeptidyl peptidase 4 (DPP-4) inhibitors, and * insulin * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening